Press Releases

09.12.2013

The treatment phase of the clinical trial phase I for MGN1703 in the U.S. was finished according to plan. In terms of safety and tolerability no significant clinical events were observed to date. The study will be completed on schedule until...

20.11.2013

The first subject has been enrolled to the clinical trial phase I for MGN1703 in the U.S. It is planned to recruit 14 healthy volunteers and to finalize the study before the end of this year. MOLOGEN expects that first results will become available...

11.11.2013

  • Three different compounds in clinical development process
  • Progress leads to slight increase in research expenses
  • Financial environment remains solid
In its report on the first nine months 2013 MOLOGEN AG reports...

28.10.2013

  • Randomized, controlled trial to evaluate efficacy
  • MGN1703 expanded by a further indication with high unmet medical need
MOLOGEN AG has submitted a clinical trial application with MGN1703 in small-cell lung cancer to the...

23.10.2013

The U.S. Food and Drug Administration (FDA) as well as the responsible Institutional Review Board have approved the phase I clinical trial with MGN1703. The placebo-controlled, double-blind study determines the cardiac safety of MGN1703 in healthy...

18.10.2013

  • Phase I trial to evaluate safety and tolerability
  • Trial is under supervision of Charité - Universitaetsmedizin Berlin
The phase I clinical trial with the cancer immune therapy MGN1404 has been started. The trial evaluates...

10.10.2013

  • Application of MGN1703 expanded by a further indication with high unmet medical need
  • Randomized, controlled trial to evaluate efficacy
  • Study will be conducted in collaboration with the German ABC group
MOLOGEN AG...

   

Displaying results 1 bis 7 von 16

Page 1

Page 2

Page 3

next

   

Contact:
Claudia Nickolaus
Head of Investor Relations & Corporate Communications

T. +49 (0) 30 - 84 17 88 - 86
F. +49 (0) 30 - 84 17 88 - 50

investor@mologen.com